201) odels compared perceived stress levels in those who did/not use exercise as a stress |
202) liances exhibited better compliance among those who had a history of previous orthod |
203) For those who had trouble understanding how to |
204) fy what is known about the debt burden on those who have been incarcerated and their |
205) higher among people with lower incomes or those who lived in more unequal communitie |
206) ly, how to make programming accessible to those who need it with a focus on organiza |
207) ups but also offered a safe sanctuary for those who needed a regulated and secure en |
208) h end of severe natural infection even in those who never had robust responses from |
209) We compared vaccine coverage between those who recalled a provider recommendati |
210) ticipants who received sertraline but not those who received PE, β = .24, p = .017, |
211) Among those who received a provider recommendati |
212) ± 7031 ng/ml, n = 32) as compared to those who remained free of intubation (336 |
213) rted no awareness of palliative care, and those who reported awareness often conflat |
214) 5% CI: 1.17-2.21, p<0.005) compared to those who reported no IPV experience. |
215) k Sacituzumab Govitecan lived longer than those who took a different chemotherapy wh |
216) All those who took part had changes in a gene |
217) b have stayed cancer-free for longer than those who took the placebo, regardless of |
218) ed experimental designs; on the contrary, those who used classical cinematherapy pro |
219) Results indicated that those who viewed the body functionality co |
220) iotics with a clinical justification with those who were given antibiotics without c |
221) Those that included a cost-effectiveness a |
222) Those that were most frequently identified |
223) y significant OS associations, defined as those that achieved p < 5 × 10-8 in |
224) For more lipophilic (basic) compounds or those that already show strong interaction |
225) se their constituent compounds as well as those that are adsorbed onto their surface |
226) ors in ALS pre-clinical models as well as those that are being studied in clinical t |
227) rmats and specimen processing to identify those that are most tolerant of conditions |
228) needed to prioritize variants, especially those that are rare or lack a definitive c |
229) that reside in the plasma membrane and of those that are secreted outside the cell. |
230) ks that performed exceptionally well were those that combined multiple standardized |
231) were screened and examined for validity, those that did not meet the inclusion crit |
232) nsive system of data-specific rules, like those that govern intellectual property. |
233) orks that developed informally as well as those that involved a formal facilitator f |
|